Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRocView Video
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investorsView Video

Latest Share Chat

Two Hutchmed drugs included in China's 2022 reimbursement list

Fri, 03rd Dec 2021 13:23

(Sharecast News) - Hutchmed China announced on Friday that, following negotiations with the China National Healthcare Security Administration (NHSA), from 1 January the updated National Reimbursement Drug List (NRDL) will continue to include 'Elunate', or fruquintinib, and would now include 'Sulanda', or surufatinib.
The AIM-traded firm said Elunate was first included in the NRDL on 1 January 2020 for the treatment of metastatic colorectal cancer, which was the third most diagnosed cancer by incidence in China in 2020, with an estimated 450,000 to 550,000 new cases each year.

Sulanda, meanwhile, was approved in the country for the treatment of advanced non-pancreatic neuroendocrine tumors in December 2020, and for advanced pancreatic neuroendocrine tumours in June of this year.

There were an estimated 71,300 newly diagnosed neuroendocrine tumor patients in China in 2020, with potentially up to 300,000 patients living with the disease.

Hutchmed said its third oncology drug, 'Orpathys', or savolitinib, was the "first and only" approved MET inhibitor in China for the treatment of patients with non-small cell lung cancer (NSCLC), with MET exon 14 skipping alterations.

It was also included in the 2021 negotiations with the NHSA, but Hutchmed, along with its partner on the drug AstraZeneca, declined inclusion in the NRDL for 2022.

The board said that position would be reassessed next year ahead of the next NRDL update.

In China, there were an estimated 13,000 newly-diagnosed NSCLC patients with MET exon 14 skipping alterations each year.

"We welcome the addition of Sulanda into the NRDL, along with the renewal of Elunate," said chief executive officer Christian Hogg.

"The NRDL has made it possible for novel therapies to gain wide reach across the country for diseases with large patient populations."

At 1441 GMT, shares in Hutchmed China were up 0.79% in London, at 511p.

Related Shares

More News
27 Mar 2024 12:02

LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data

(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the...

27 Mar 2024 11:56

C4X Discovery seeks AIM delisting but half-year revenue skyrockets

(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downt...

27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

27 Mar 2024 09:03

LONDON MARKET OPEN: FTSE 100 slips as unease lingers before US data

(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the w...

27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation readin...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.